BioCentury | Jun 22, 2019
Clinical News

June 21 Clinical Quick Takes: Melanoma miss for Exelixis/Genentech combo; plus Progenics, Turning Point, Gracell

...Prevention Pharmaceuticals Inc. (Tucson, Ariz.) said it hopes to seek U.S. and EU approval for CPP-1X/sulindac...
...progression to any FAP-related event, the primary endpoint in the Phase III CPP FAP-310 trial, CPP-1X/sulindac...
...131, ultratrace i-131-mibg, ultratrace iobenguane i 131) Cotellic, cobimetinib (GDC-0973, RG7421, xl518, MEK inhibitor) DFMO/sulindac, eflornithine/sulindac (CPP-1X/sul, CPP-1X/sulindac) repotrectinib...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
BioCentury | Jan 5, 2018
Company News

Mallinckrodt acquiring Sucampo

...to close next quarter. Mallinckrodt will gain two late-stage rare disease candidates -- VTS-270 and CPP-1X/sulindac...
...and sphingolipid storage through its April acquisition of Vtesse Inc. (see BioCentury, April 6 ). CPP-1X/sulindac...
...for North American commercialization rights to CPP-1X/sulindac. An NDA submission is slated for early 2019. CPP-1X/sulindac...
BioCentury | Dec 26, 2017
Company News

Mallinckrodt acquiring Sucampo

...slated to close next quarter. Mallinckrodt will gain two late-stage rare disease candidates: VTS-270 and CPP-1X/sulindac...
...sphingolipid storage through its April acquisition of Vtesse Inc. (see BioCentury Extra, April 3) . CPP-1X/sulindac...
...for North American commercialization rights to CPP-1X/sulindac. An NDA submission is slated for early 2019. CPP-1X/sulindac...
BioCentury | Jun 23, 2017
Clinical News

IDMC recommends continuation of Cancer Prevention's Phase III FAP trial

...said an IDMC recommended continuation of the Phase III CPP FAP-310 trial evaluating eflornithine/sulindac (DFMO/sulindac, CPP-1X/sulindac...
...Zeria Pharmaceutical Co. Ltd. (Tokyo:4559) has exclusive rights from Cancer Prevention to develop and commercialize eflornithine/sulindac...
...Tucson, Ariz. Zeria Pharmaceutical Co. Ltd. (Tokyo:4559), Tokyo, Japan Product: Eflornithine/sulindac ( DFMO/sulindac , CPP-1X/sulindac...
BioCentury | Apr 11, 2016
Clinical News

Eflornithine/sulindac: Completed Phase III enrollment

...for 2 years. Zeria’s Tillotts Pharma AG subsidiary has exclusive rights to develop and commercialize eflornithine/sulindac...
...Tucson, Ariz. Zeria Pharmaceutical Co. Ltd. (Tokyo:4559), Tokyo, Japan Product: Eflornithine/sulindac ( DFMO/sulindac ) ( CPP-1X/sulindac...
BioCentury | Feb 1, 2016
Company News

Cancer Prevention Pharmaceuticals, Sucampo deal

...commercialize CCP-1X/sulindac in North America. Cancer Prevention will complete the ongoing Phase III trial of CPP-1X/sulindac...
...polyposis (FAP) under a joint steering committee. The company expects to complete enrollment this half. CPP-1X/sulindac...
BioCentury | Apr 23, 2015
Distillery Therapeutics

Therapeutics: Arginase 1 (ARG1)

...Alzheimer's", page 13) Cancer Prevention Pharmaceuticals Inc. and Zeria Pharmaceutical Co. Ltd. have CPP-1X/sulindac ( DFMO/sulindac...
BioCentury | Jan 13, 2014
Company News

Cancer Prevention Pharmaceuticals, Zeria deal

...Cancer Prevention granted Zeria's Tillotts Pharma AG subsidiary exclusive rights to develop and commercialize CPP-1X/sulindac in...
...development of multiple benign polyps in the colon that can become cancerous if left untreated. CPP-1X/sulindac...
BioCentury | Dec 9, 2013
Clinical News

DFMO/sulindac: Phase III started

...patients with FAP. Cancer Prevention Pharmaceuticals Inc. , Tucson, Ariz. Product: DFMO/sulindac , eflornithine/sulindac ( CPP-1X/sulindac...
Items per page:
1 - 10 of 12